Eli Lilly and Company (LLY)
| Market Cap | 962.96B |
| Revenue (ttm) | 59.42B |
| Net Income (ttm) | 18.41B |
| Shares Out | 895.38M |
| EPS (ttm) | 20.44 |
| PE Ratio | 52.61 |
| Forward PE | 34.56 |
| Dividend | $6.00 (0.56%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 2,732,117 |
| Open | 1,096.72 |
| Previous Close | 1,104.34 |
| Day's Range | 1,067.69 - 1,099.05 |
| 52-Week Range | 623.78 - 1,111.99 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 1,057.89 (-1.63%) |
| Earnings Date | Oct 30, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,057.89, which is a decrease of -1.63% from the latest price.
News
Is Eli Lilly a Millionaire Maker?
Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs.
These Are 2 of the Smartest Growth Stocks to Invest $5,000 in Today
Both of these stocks are growing by leaps and bounds. MercadoLibre boasts a cohesive ecosystem that is driving revenue and profits forward.
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.
Don't expect much from Eli Lilly stock anymore, says Len Yaffee
Market expert Len Yaffee says it would be increasingly difficult for Eli Lilly (NYSE: LLY) to push higher from current levels – at least in the near-term. LLY shares have been standout performers in 2...
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031
Eli Lilly's valuation may suggest that its market-beating days are behind it. However, the pharmaceutical giant still has significant momentum.
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.
Stock Split Watch: Is Eli Lilly Next?
Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company's portfolio of weight loss drugs, which has generated blockbuster revenue.
Wall Street Breakfast Podcast: HP Downsizes To Power Up
HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on O...
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast cancer to be presented as a late-break...
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Josh Brown's ‘best stocks in the market': Health Care
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he's spotlighting Health Care in his "best stocks in the market." The Committee debates their health care s...
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare.
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...
Eli Lilly Stock Joins $1 Trillion Club: What Is Happening?
Eli Lilly's stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement sur...
Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound
Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ago...
2 Top Dividend Stocks for Growth-Oriented Investors
Alphabet's dividend is still new but looks secure given its fantastic business and growth prospects. Eli Lilly is increasing its top line at a dizzying pace and has a strong dividend growth record ove...
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes will help it catch up.
Eli Lilly Stock Value Tops $1 Trillion. Learn Why And If To Buy $LLY
Eli Lilly stock has risen 36% this year to reach a $1 trillion market capitalization – the first health-care company to reach this milestone, according to CNBC.
Eli Lilly: The Weight-Loss Leader With More Upside If Execution Holds
Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top...
When Investors Panic, I Buy Eli Lilly
Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and...
The Score: Nvidia, Constellation, Eli Lilly, Gap and More Stocks That Defined the Week
The Score is a weekly review of the biggest stock moves and the news that drove them.
LLY Becomes Biggest Healthcare Company: Analyzing Stock's Stunning Rally
Eli Lilly (LLY) became the 10th U.S. company to tap $1 trillion in market cap and has outperformed most of its peers, particularly its biggest rival, Novo Nordisk (NVO). Rick Ducat shows just how mass...
Eli Lilly becomes first health-care company to hit $1 trillion
Silicon Valley's giants crowd the list of the world's most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of one trillion dollars on Frid...
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl...
AI Stocks Are Taking a Beating. What to Buy Instead.
Healthcare stocks may have more momentum. But the AI trade isn't dead yet.